The effect of anemia treatment on selected health-related quality-of-life domains: A systematic review

Clinical Therapeutics

Volumn 25, Issue 6, 2003, Pages 1786-1805

  Ross, Susan D ^a   Fahrbach, Kyle ^a   Frame, Diana ^a   Scheye, Rachel ^a   Connelly, Janet E ^a   Glaspy, John ^b  

^a MetaWorks Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anemia; Cancer; Erythropoiesis stimulating protein; Hematocrit; Quality of life; Renal insufficiency

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DISEASE DURATION; DYSPNEA; ENERGY; ERYTHROCYTE; FATIGUE; HEADACHE; HEALTH CARE QUALITY; HEMATOCRIT; HUMAN; HYPOTHESIS; KIDNEY FAILURE; MAJOR CLINICAL STUDY; META ANALYSIS; OXYGEN CONSUMPTION; PHYSICAL ACTIVITY; PREDICTION; PROTEIN ANALYSIS; QUALITY OF LIFE; REGRESSION ANALYSIS; REVIEW; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; VERTIGO;

EID: 0038354877     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80170-4     Document Type: Editorial

References (67)

1. Celia D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997;34(Suppl 2):13-19.
2. Glaspy J, Bukowski R, Steinberg D, et al, for the Procrit Study Group. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol. 1997;15:1218-1234.
3. Cella DF. Measuring quality of life in palliative care. Semin Oncol. 1995;22(Suppl 3):73-81.
4. Cella DF, Bonomi AE. Measuring quality of life: 1995 Update. Oncology (Huntingt). 1995;9(Suppl 11):47-60.
5. Seidenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: A systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst. 2001;93:1204-1214.
6. Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: Synthesis of best evidence for clinical decisions. Ann Intern Med. 1997;126:376-380.
7. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: L. Erlbaum Associates; 1988.
8. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-748.
9. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
10. Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. San Diego, Calif: Academic Press; 1985.
11. Cooper H, Hedges LV. The Handbook of Research Synthesis. New York: Russell Sage Foundation; 1994.
12. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ. 1990;300:573-578
13. Auer J, Simon G, Stevens J, et al. Quality of life improvements in CAPD patients treated with subcutaneously administered erythropoietin for anemia. Perit Dial Int. 1992;12:40-42.
14. Beusterien KM, Nissenson AR, Port FK, et al. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol. 1996;7:763-773.
15. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a Phase III multicenter clinical trial. Ann Intern Med. 1989;111:992-1000.
16. Foley RN, Parfrey PS, Morgan J, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 2000;58:1325-1335.
17. Harris DC, Chapman JR, Stewart JH, et al. Low dose erythropoietin in maintenance haemodialysis: Improvement in quality of life and reduction in true cost of haemodialysis. Aust N Z J Med. 1991;21:693-700.
18. Hurtado I, Enamorado A, Otero H, Bohorques R. Study of quality of life of patients on maintenance hemodialysis before and after the use of erythropoietin [in Spanish]. Nefrologia. 2000;20:445-447.
19. Kleinman KS, Schweitzer SU, Perdue ST, et al. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: A double-blind, placebo-controlled trial. Am J Kidney Dis. 1989;14:486-495.
20. McMahon LP, Mason K, Skinner SL, et al. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant. 2000;15:1425-1430.
21. Moreno F, Aracil FJ, Perez R, Valderrabano F. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin. Am J Kidney Dis. 1996;27:548-556.
22. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, et al, for the Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. J Am Soc Nephrol. 2000;11:335-342.
23. Muirhead N, Cattran DC, Zaltzman J, et al. Safety and efficacy of recombinant human erythropoietin in correcting the anemia of patients with chronic renal allograft dysfunction. J Am Soc Nephrol. 1994;5:1216-1222.
24. Muirhead N, Churchill DN, Goldstein M, et al. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease. Am J Nephrol. 1992;12:303-310.
25. Roth D, Smith RD, Schulman G, et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis. 1994;24:777-784.
26. Tsai JC, Lai YH, Tsai ZY, et al. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: Influence of dosing regimen, iron status, and serum aluminum. Gaoxiong Yi Xue Ke Xue Za Zhi. 1991;7:126-135.
27. Wolcott DL, Marsh JT, La Rue A, et al. Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. Am J Kidney Dis. 1989;14:478-485.
28. Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer. 1993;29A(Suppl 2): S2-S8.
29. Chiou TJ, Chim YS, Wei CH, et al. The effect of subcutaneous r-HuEPO in cancer patients receiving chemotherapy with anemia: A preliminary report. Zhonghua Yi Xue Za Zhi (Taipei). 1997;60:229-235.
30. Demetri GD, Kris M, Wade J, et al, for the Procrit Study Group. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. J Clin Oncol. 1998;16:3412-3425.
31. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 2001;19:2875-2882.
32. Johansson JE, Wersall P, Brandberg Y, et al. Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer - a randomized study. Scand J Urol Nephrol. 2001;35:288-294.
33. Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer. 1994;73:2535-2542.
34. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865-2874.
35. Ludwig H, Fritz E, Leitgeb C, et al. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol. 1993;4:161-167.
36. Ludwig H, Sundal E, Pecherstorfer M, et al. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer. 1995;76:2319-2329.
37. Mittelman M, Zeidman A, Fradin Z, et al. Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia. Acta Haematol. 1997;98:204-210.
38. Pawlicki M, Jassem J, Bosze P, et al. A multicenter study of recombinant human erythropoietin (epoetin alpha) in the management of anemia in cancer patients receiving chemotherapy. Anticancer Drugs. 1997;8:949-957.
39. Quirt I, Robeson C, Lau CY, et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol. 2001;19:4126-4134.
40. Siakantaris MP, Angelopoulou MK, Vassilakopoulos TP, et al. Correction of disease related anaemia of B-chronic lymphoproliferative disorders by recombinant human erythropoietin: Maintenance is necessary to sustain response. Leuk Lymphoma. 2000;40:141-147.
41. Smith RE Jr, Jaiyesimi IA, Meza LA, et al. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J Cancer. 2001;84(Suppl 1):24-30.
42. Thatcher N, De Campos ES, Bell DR, et al. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer. 1999;80:396-402.
43. Gough IR, Furnival CM, Schilder L, Grove W. Assessment of the quality of life of patients with advanced cancer. Eur J Cancer Clin Oncol. 1983;19:1161-1165.
44. McCormack HM, Horne DJ, Sheather S. Clinical applications of visual analogue scales: A critical review. Psychol Med. 1988;18:1007-1019.
45. Maxwell C. Sensitivity and accuracy of the visual analogue scale: A psycho-physical classroom experiment. Br J Clin Pharmacol. 1978;6:15-24.
46. Bond A, Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol. 1974;47:211-218.
47. Hunt SM, McKenna SP, McEwen J, et al. The Nottingham Health Profile: Subjective health status and medical consultations. Soc Sci Med [A]. 1981;15:221-229.
48. Hunt SM, McEwen J. The development of a subjective health indicator. Sociol Health Illn. 1980;2:231-246.
49. O'Brien BJ, Buxton MJ, Ferguson BA. Measuring the effectiveness of heart transplant programmes: Quality of life data and their relationship to survival analysis. J Chronic Dis. 1987;40(Suppl 1):137S-158S.
50. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: Development and final revision of a health status measure. Med Care. 1981;19:787-805.
51. Stewart AL, Ware JE Jr, eds. Measuring Functioning and Well-Being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press; 1992.
52. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Status Survey Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Center; 1993.
53. McHorney CA, Ware JE Jr, Rogers W, et al. The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts. Results from the Medical Outcomes Study. Med Care. 1992;30(Suppl 5):MS253-MS265.
54. Laupacis A, Muirhead N, Keown P, Wong C. A disease-specific questionnaire for assessing quality of life in patients on hemodialysis. Nephron, 1992;60:302-306.
55. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol. 1993;11:570-579.
56. Yellen SB, Cella DF, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13:63-74.
57. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376.
58. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, ed. Evaluation of Chemotherapeutic Agents. New York: Columbia University Press; 1949:191-205.
59. Sorensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer. 1993;67:773-775.
60. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
61. Strippoli GF, Manno C, Schena FP, Craig JC. Haemoglobin and haematocrit targets for the anaemia of chronic renal disease. Cochrane Database Syst Rev. 2003;(1):CD003967.
62. McClellan WM, Anson C, Birkeli K, Tuttle E. Functional status and quality of life: Predictors of early mortality among patients entering treatment for end stage renal disease. J Clin Epidemiol. 1991;44:83-89.
63. Conill C, Verger E, Salamero M. Performance status assessment in cancer patients. Cancer. 1990;65:1864-1866.
64. Jaeschke R, Singer J, Guyatt G. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10:407-415.
65. Lydick E, Epstein RS. Interpretation of quality of life changes. Qual Life Res. 1993;2:221-226.
66. Guyatt GH. Making sense of quality-of-life data. Med Care. 2000;38(Suppl): II175-II179.
67. Hays RD, Woolley JM. The concept of clinically meaningful difference in health-related quality-of-life research. How meaningful is it? PharmacoEconomics. 2000;18:419-423.